It stimulates your body to make more insulin after you eat, prevents your liver from releasing stored sugar, and slows the movement of food through your body
The methionine sulfoxide reduction system: Selenium utilization and methionine sulfoxide reductase enzymes and their functions
Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker
Do not freeze Zepbound
3 This included a broad population where 69% of participants had no prior cardiovascular disease, suggesting benefit for primary prevention
Clinical trial entry usually depends on factors such as BMI, medical history, existing health conditions, current medication and location